Skip to main content
. Author manuscript; available in PMC: 2010 Oct 1.
Published in final edited form as: Mol Cancer Ther. 2009 Oct;8(10):2882–2893. doi: 10.1158/1535-7163.MCT-09-0293

Figure 4. Effect of SGI-1776 on inhibiting Pim kinase activity in prostate cancer cells stably overexpressing recombinant Pim-1.

Figure 4

(A) Cell growth over a period of 72 hours was established in the 22Rv1 and 22Rv1-Pim1 cell lines using the ATP viability assay. The results are displayed as an average of four individual wells at each time point. (B) Phospho-p21Thr145 and total p21 protein levels were examined in 22Rv1 and 22Rv1-Pim1 cells after treatment with increasing doses of SGI-1776 for 2 hours. (C) Cell viability was compared between 22Rv1 and 22Rv1-Pim1 cells treated with increasing concentrations of SGI-1776 after 72 hours. The results are displayed as an average of four individual wells. (D) Caspase-3 activity was determined using a fluorometric protease assay after treatment with increasing doses of SGI-1776 for 72 hours. The samples were run in triplicate and the results were normalized to untreated samples.